Autoimmune RORγt Program May Portend Change Of Direction For Vitae

Vitae Pharmaceuticals Inc. tells a different story than many other clinical-stage companies, but then how many biotechs without a commercial product have not needed to raise funds in nearly nine years? Focused on structure-based drug design, the Ft. Washington, Pa., firm is nearing an inflection point as it decides which among several suitors to partner with on a ROR gamma t inhibitor program that could offer utility in multiple autoimmune indications.